BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 30, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 6/27 cls
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Wells Fargo Brian Abrahams Upgrade Outperform (from market perform) 6% $12.52
Abrahams also increased his target to $17-$19 from $8-$9 after discussions with key opinion leaders suggest the current valuation does not fully reflect the likelihood of success and long-term opportunity for BCX4161 to treat...

Read the full 485 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >